Salim Laghouati

Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors: The SACHA-France experience.

Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors: The SACHA-France experience.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 16, 2026

Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry.

Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: February 21, 2025

Centralized Investigator Review of Radiological and Functional Imaging Reports in Real-World Oncology Studies: The SACHA-France Experience.

Centralized Investigator Review of Radiological and Functional Imaging Reports in Real-World Oncology Studies: The SACHA-France Experience.

Journal: Pediatric blood & cancer

Published: October 03, 2024

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 06, 2024

Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?

Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 16, 2024

Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.

Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.

Journal: Trials

Published: July 11, 2023

Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.

Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.

Journal: JAMA network open

Published: July 03, 2023

ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.

ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.

Journal: Trials

Published: March 01, 2023

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.

Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.

Journal: Cancer discovery

Published: August 08, 2022

Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.

Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 01, 2022

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.

Journal: Cancer treatment reviews

Published: March 14, 2022

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.

Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 31, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026